Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia

Atherosclerosis

Volumn 214, Issue 1, 2011, Pages 144-147

  Koh, Kwang Kon ^a   Quon, Michael J ^b   Lim, Soo ^c   Lee, Yonghee ^d   Sakuma, Ichiro ^e   Lee, Youn Hee ^a   Han, Seung Hwan ^a   Shin, Eak Kyun ^a  

^a Gachon University   (South Korea)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Seoul National University Bundang Hospital   (South Korea)

^d University of Seoul   (South Korea)

^e Hokko Memorial Clinic   (Japan)

Author keywords

Adipocytokines; Endothelial function; Fenofibrate; Hypertriglyceridemia; Insulin resistance

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; FENOFIBRATE; GLYCOSYLATED HEMOGLOBIN; LEPTIN; PLACEBO; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADIPOKINES; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; FEMALE; FENOFIBRATE; HEMOGLOBINS; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLACEBOS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650828581     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.023     Document Type: Article

References (15)

1. Han S.H., Quon M.J., Koh K.K. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor (PPAR)α activators. Hypertension 2005, 46:1086-1092.
2. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000, 47:648-657.
3. Kim J., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
4. Han S.H., Quon M.J., Kim J.A., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007, 49:531-538.
5. Koh K.K., Park S.M., Quon M.J. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008, 117:3238-3249.
6. Verma S., Li S.H., Wang C.H., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740.
7. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687-3692.
8. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410.
9. Tsuchida A., Yamauchi T., Takekawa S., et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha. PPARgamma, and their combination. Diabetes 2005, 54:3358-3370.
10. Choi K.C., Ryu O.H., Lee K.W., et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005, 336:747-753.
11. Lee H.J., Choi S.S., Park M.K., et al. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 2002, 296:293-299.
12. Ohmori R., Momiyama Y., Kato R., et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005, 46:379-380.
13. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Eng J Med 2010; 362:1563-74.
14. The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010. doi:10.1056/NEJMoa1001288.
15. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.